Development of an RXR Agonist Scaffold with Pronounced Homodimer Preference

Area of Science:

• Molecular Biology
• Pharmacology
• Drug Discovery

Background:

• Retinoid X receptors (RXRs) are crucial in nuclear receptor signaling, involved in diverse conditions like cancer and neurodegeneration.
• Current RXR agonists often exhibit promiscuous effects due to RXR's role in various dimeric forms.

Purpose of the Study:

• To identify and optimize a novel RXR ligand chemotype with selective activity.
• To investigate the potential for modulating specific RXR signaling pathways.

Main Methods:

• Identification of a new RXR ligand chemotype.
• Chemical optimization of the lead compound.
• Biochemical assays to assess homodimer and heterodimer activation.
• Co-crystal structure analysis of the RXR ligand-bound receptor.

Main Results:

• A novel RXR modulator scaffold was developed with nanomolar potency for RXR homodimer activation.
• The new modulator showed significantly reduced activation of RXR heterodimers compared to bexarotene.
• Co-crystal structures revealed distinct interactions with the RXR ligand-binding domain (LBD) compared to bexarotene.

Conclusions:

• The novel RXR modulator enables selective studies of RXR homodimer activation effects.
• This discovery suggests that distinct molecular mechanisms of RXR activity can be therapeutically targeted.
• This represents a significant advancement in developing more specific RXR-targeting drugs.